WHO ICTRP trial
Safety, clinical tolerability and immune activity of increasing doses of the…
EUCTR2013-000056-18-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-000056-18-DE |
|---|---|
| Public title | Safety, clinical tolerability and immune activity of increasing doses of the investigational medicinal product gpASIT+TM administered under the skin to patients suffering from hay fever. |
| Scientific title | Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study. |
| Primary sponsor | BioTech Tools S.A. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Treatment of seasonal grass pollen rhinoconjunctivitis. MedDRA version: 15.1 Level: LLT Classification code 10019170 Term: Hay fever System Organ Class: 100000004870 ;Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09] |
| Interventions | Product Name: gpASIT+TM Pharmaceutical Form: Solution for injection |
| Registration date | Apr 2, 2013 |
| Secondary IDs | BTT-gpASIT007 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: